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Abstract
The epigenetic impact of DNA methylation in chronic myelogenous leukemia (CML) is not completely understood. To
elucidate its role we analyzed 120 patients with CML for methylation of promoter-associated CpG islands of 10 genes. Five
genes were identified by DNA methylation screening in the K562 cell line and 3 genes in patients with myeloproliferative
neoplasms. The CDKN2B gene was selected for its frequent methylation in myeloid malignancies and ABL1 as the target of
BCR-ABL translocation. Thirty patients were imatinib-naı ¨ve (mostly treated by interferon-alpha before the imatinib era), 30
were imatinib-responsive, 50 were imatinib-resistant, and 10 were imatinib-intolerant. We quantified DNA methylation by
bisulfite pyrosequencing. The average number of methylated genes was 4.5 per patient in the chronic phase, increasing
significantly to 6.2 in the accelerated and 6.4 in the blastic phase. Higher numbers of methylated genes were also observed
in patients resistant or intolerant to imatinib. These patients also showed almost exclusive methylation of a putative
transporter OSCP1. Abnormal methylation of a Src suppressor gene PDLIM4 was associated with shortened survival
independently of CML stage and imatinib responsiveness. We conclude that aberrant DNA methylation is associated with
CML progression and that DNA methylation could be a marker associated with imatinib resistance. Finally, DNA methylation
of PDLIM4 may help identify a subset of CML patients that would benefit from treatment with Src/Abl inhibitors.
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Introduction
DNA methylation in promoter-associated CpG islands is a
powerful mechanism of gene silencing that is one of the drivers of
neoplastic transformation through the inactivation of critical
tumor-suppressor pathways [1]. DNA hypermethylation is com-
monly seen in various types of leukemia including acute myeloid
leukemia [2], acute lymphoblastic leukemia [3], chronic lympho-
cytic leukemia [4,5,6], and it has recently been shown to predict
outcomes in some patients with myelodysplastic syndrome [7,8].
Etiologically, chronic myelogenous leukemia (CML) is a homoge-
neous genetic disease, as it is triggered by the aberrant tyrosine
kinase activity of the BCR-ABL translocation [9].
Despite genetic homogeneity, there is considerable heterogene-
ity in the clinical course of CML: it progresses at a varying rate
from the chronic phase (CP) to the accelerated phase (AP) and
eventually to the blastic phase (BP). Tyrosine kinase inhibitors such
as imatinib mesylate (imatinib) are very effective in treating
chronic-phase CML but considerably less effective in treating
blastic-phase CML [10]. This heterogeneity in disease progression
and response to imatinib therapy is likely due to molecular events
that follow the initial BCR-ABL translocation. Aberrant hyper-
methylation has been previously described in CML [11,12,
13,14,15,16]. The translocated ABL1 promoter shows allele-
specific de novo methylation early on in the course of the disease,
a phenomenon that is unique to CML [14,17]. A few studies have
examined the methylation status of individual tumor-suppressor
genes in CML, with results ranging from rare or no hypermethy-
lation (e.g., SFRP1, RASSF1A) [18,19] to hypermethylation at
progression (e.g., CALCA, CDKN2B, EBF2, ESR, HIC1, TFAP2A,
and others) [11,12,13,20]. Hypermethylation of ATG16L2 gene
promoter has been associated with a poor response to imatinib
treatment [20]. However, these studies have been limited by the
relatively random choice of genes examined, which was based on
studies of other malignancies.
Here, we report on the methylation status of a set of 10 genes.
Five genes were selected based on our genome wide methylation
studies in the K562 leukemia cell line [21] and 3 genes based on
our genome wide screening in patients with myeloproliferative
neoplasms [22]. We have also included the CDKN2B gene, deleted
in K562 and frequently methylated myeloid malignancies [23],
and the ABL1 gene as the target of BCR-ABL translocation. We
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22110found that DNA methylation was strongly associated with disease
progression and resistance to imatinib in CML.
Methods
Patients and cell line
We examined gDNA from peripheral blood mononuclear cells
of 120 patients with CML at various phases (65 in CP, 40 in AP,
and 15 in BP) that had been treated at The University of Texas
MD Anderson Cancer Center (Houston, TX). The median age
was 50 years (range 16–80 years), 79 patients (65%) were male.
One set of samples from 30 patients that had been collected
between November 1988 and June 1993 was studied to
determine the effect of DNA methylation on CML progression
prior to the imatinib era (i.e., imatinib-naı ¨ve patients). Most of
these patients had been treated with interferon-alpha–based
regimens. Another set of samples from 90 patients treated in the
imatinib era was obtained between July 2001 and November
2004. Of these 90 patients, 30 were imatinib-responsive (27 in
CP, 2 in AP and 1 in BP), 50 were imatinib-resistant (10 in CP,
28 in AP and 12 in BP), and 10 were imatinib-intolerant (6 in CP,
4 in AP and 0 in BP). None of the patients had been previously
treated with hypomethylating drugs. Clinical and hematological
data of the patients are summarized in Table 1. For normal
controls, peripheral white blood cells (WBC) were collected from
22 healthy volunteers (18–53 years of age). The Institutional
Review Board at MD Anderson approved all protocols, and all
patients gave informed consent for the collection of residual
tissues as per institutional guidelines and in accordance with the
Declaration of Helsinki.
The leukemia cell line K562 used in this study was obtained
from the American Type Culture Collection (Manassas, VA,
USA).
Methylated CpG island amplification microarray (MCAM)
analysis
We used gDNA from the CML-derived K562 cell line [24]
and, as a control, a DNA pool made from WBC of 4 healthy
donors. In separate MCAM experiments (data not shown), we
found minimal differences in DNA methylation of the analyzed
CpG sites between CD34
+ bone marrow cells and unsorted
WBC, suggesting that the chosen control was appropriate for
MCAM analysis. Methylated CpG island amplification (MCA)
was performed as described previously [25]. Amplicons from the
K562 cell line were labeled with the Cy5 dye and cohybridized
against amplicons from WBC control labeled with the Cy3 dye
on Agilent Technologies 4644 K custom DNA microarrays
(Agilent, Santa Clara, CA) as described previously [2]. MCAM
for K562 was performed as a single array experiment.
Fluorescence signals were lowess normalized and trimmed
averages of normalized log2 ratios were calculated for amplicons
covered by multiple probes. Hypermethylation was defined as
normalized log2 ratio of Cy5/Cy3 fluorescence greater than 1
(equivalent to 2-fold and higher K562/WBC signal intensity).
MCAM has been extensively validated by independent bisulfite-
based methods showing the sensitivity of 88% and the specificity
of 96% [26]. Enrichment for Polycomb targets was performed
by comparing genes differentially methylated in the K562 cell
line with the list of targets of H3K27 trimethylation in human
embryonic stem cells [27] that were present on our array. The
Table 1. Characteristics of the patients.
Parameter Pre-imatinib Imatinib era
Sample dates 11/1988–06/1993 07/2001–11/2004
Total patients 30 90
Age, years; median (range) 42 (16–69) 54 (23–80)
Males 20 (67%) 58 (64%)
CML stage
chronic 21 43
accelerated 73 4
blastic 21 3
Imatinib status
naı ¨ve 30 0
responsive N/A 30
resistant N/A 50
intolerant N/A 10
Hematological parameters
WBC, 10‘3/uL; median (range) 119 (2–366) 23 (3–317)
Peripheral blood blasts, %; median (range) 2 (0–92) 1 (0–99)
Peripheral blood basophils, %; median (range) 2 (0–22) 3 (0–36)
Hemoglobin, g/dL; median (range) 11.4 (5.8–15.2) 10.9 (6.8–16.6)
Platelets, 10‘3/uL; median (range) 259 (50–1205) 222 (10–1245)
Bone marrow blasts, %; median (range) 2 (0–91) 2 (0–94)
Bone marrow basophils, %; median (range) 2 (0–11) 3 (0–27)
doi:10.1371/journal.pone.0022110.t001
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GNF1H data sets [28] available from the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/).
DNA methylation analysis by bisulfite pyrosequencing
We isolated gDNA from peripheral blood mononuclear cells
after Ficoll separation using standard phenol-chloroform extrac-
tion. We selected 10 genes and the LINE-1 repetitive element for
quantitative analysis of DNA methylation by bisulfite pyrose-
quencing as described previously [2,29]. Our pyrosequencing
assays interrogated 2–6 adjacent CpG sites close to gene
transcription start site (Table 2). Methylation status of consecutive
CpG sites has a high concordance in regions spanning several
hundred bases [30]. Therefore, we used mean values from all
pyrosequenced CpG sites as a measure of methylation of a given
gene. For each assay, we determined the range of normal values by
measuring the DNA methylation levels in 18–22 healthy controls.
Methylation values exceeding the maximum value detected in
normal controls were considered abnormal. This criterion was
more stringent that the 95% confidence interval. Genomic
location of the bisulfite pyrosequencing assays and the number
of investigated CpG sites in each assay are shown in Table 2. The
sequences of PCR primers and annealing temperatures are listed
in Table S1.
Statistical analysis
Lowess normalization and analysis of MCAM data were
performed as described [26]. To analyze enrichment for
Polycomb targets the chi-square test was used, and odds ratio
for enrichment was calculated. Pathways affected by aberrant
methylation of multiple genes were identified with Ingenuity
Pathway Analysis software (Ingenuity Systems, Redwood City,
CA). We used the Wilcoxon signed rank nonparametric test to
compare the expression of genes in K562 and normal white blood
cells. We used the Spearman nonparametric correlation test to
compare bisulfite pyrosequencing methylation data between
individual genes. We used the chi-square and Fisher’s exact tests
to compare DNA methylation data with clinical parameters. We
performed multivariate analysis using Cox’s regression and
forward stepwise likelihood ratio model to find independent
prognostic variables. We used Kaplan-Meier logrank tests to
calculate and generate overall survival curves for independent
variables. Two-tailed P values of 0.05 or less were considered
statistically significant. We used GraphPad Prism 5 (GraphPad
Software, La Jolla, CA) and PASW Statistics 17.0 to perform
statistical analyses.
Results
MCAM analysis
We observed hypermethylation in the K562 cell line in 4,138 of
27,890 (15%) total CpG sites analyzed by MCAM (Figure 1).
When we focused on CpG sites within 500 bp from TSS, we
detected hypermethylation in 1,014 of 7,246 (14%) RefSeq
autosomal genes analyzed. The complete list of methylated genes
is provided in Table S2. The methylated genes showed an
enrichment for targets of Polycomb (PCG) silencing in embryonic
stem cells. The microarray we used for MCAM could detect
methylation status of 5,143 autosomal genes with available
information on PCG targeting in ES cells [27]. Among 688 genes
showing hypermethylation, 178 genes (25.8%) were PCG targets.
Among 4,455 unmethylated genes, only 491 genes (11.0%) were
PCG targets, odds ratio 2.8 (95% confidence interval 2.3 to 3.4,
P,.0001, Table S3). Analysis of pathways affected by methylation
of multiple genes revealed a significant enrichment for genes
involved in cellular development (201 genes, P,.01), cell death
(190 genes, P,.01), and gene expression (149 genes, P,.01). The
list of gene categories significantly affected by DNA methylation is
shown in Table S4. Based on the Gene Expression Omnibus
GNF1H data sets, the hypermethylated genes as detected by
MCAM also had a significantly lower expression in the K562 cell
line than in normal white blood cells (P=.002; Figure 2).
Bisulfite pyrosequencing analysis
We selected 10 genes for quantitative analysis of DNA
methylation by bisulfite pyrosequencing in CML patients. DPYS,
NPM2, OSCP1, PDLIM4 and TFAP2E genes were found
hypermethylated, and CDKN2B (p15
INK4B) homozygously deleted
in the K562 leukemia cell line. ABL1 is the subject of BCR-ABL
translocation and is methylated exclusively on the Philadelphia
chromosome. CDH13, PGR-A and B isoforms were identified by a
genome wide screening as hypermethylated in patients with
myeloproliferative neoplasms [22]. We also analyzed methylation
of the LINE-1 repetitive element, as a surrogate marker of global
genomic methylation [31]. A summary of the results of the DNA
methylation analysis in 120 patients with CML is shown in
Table 3. The most frequently methylated genes in more than 70%
patients across all CML stages were ABL1, CDH13 and NPM2.
Interestingly, about half of CML patients also showed an increase
Table 2. Genomic location of bisulfite pyrosequencing assays.
Gene Location of pyrosequencing target (hg18) Distance from TSS CpG sites in assay
ABL1 chr9:132,700,627–132,700,645 224 to 214 3
CDH13 chr16:81,218,151–81,218,189 +74 to +102 6
CDKN2B chr9:21,999,154–21,999,185 +127 to +147 4
DPYS chr8:105,548,436–105,548,480 227 to +17 4
NPM2 chr8:21,938,232–21,938,267 266 to 241 6
OSCP1 chr1:36,688,776–36,688,815 237 to 220 5
PDLIM4 chr5:131,621,029–131,621,064 2221 to 2192 6
PGR-A chr11:100,504,896–100,504,924 +261 to +289 4
PGR-B chr11:100,505,573–100,505,605 +860 to +892 4
TFAP2E chr1:35,811,437–35,811,445 2121 to 2113 2
doi:10.1371/journal.pone.0022110.t002
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range. However, only 4 patients (3%) showed LINE-1 methylation
below the normal range. The differences in LINE-1 methylation
between individual stages of CML were not significant (Table S5).
DNA methylation is increased in advanced CML
Five of the 10 studied genes showed a significant methylation
increase in CML progressed to AP or BP stages. These included
CDKN2B, OSCP1, PGRA, PGRB and TFAP2E genes (Table 3). We
next calculated the sums of methylated and unmethylated genes in
individual patients and analyzed the proportions of methylated
and unmethylated genes in CML stages. On average, 4.5 genes
were methylated in CP, 6.2 genes in AP and 6.8 genes in BP
(Table 4). The increase in the number of methylated genes in
advanced stages was statistically significant (P,.0001, chi-square
test). Of 64 patients in CP, 1 patient (2%) had no hypermethylated
gene and 21 patients (33%) had more than 5 hypermethylated
genes. Of 41 patients in AP, no patient (0%) had zero
hypermethylated genes and 25 patients (61%) had more than 5
hypermethylated genes. Of 15 patients in BP, no patient (0%) had
no hypermethylated gene and 12 patients (80%) had more than 5
hypermethylated genes. There was no significant difference in
overall survival between 35 CP patients with 0–4 hypermethylated
genes and 29 CP patients with 4–10 hypermethylated genes.
Methylation levels showed positive correlations between individual
genes (Table S6). Methylation of the DPYS gene was signicantly
correlated with 6 other genes, suggesting this gene may be a part of
a potential hypermethylator phenotype and a shared etiology for
increased methylation in a subset of affected cases. On the other
hand, the PDLIM4 gene stood out showing no significant
correlation with any of the other analyzed genes.
DNA methylation is increased in imatinib resistant and
intolerant patients
To assess a possible epigenetic component of imatinib
resistance, we compared DNA methylation in patients responsive,
intolerant and resistant to imatinib. Patients in CP that were
responsive to imatinib had on average 3.9 methylated genes, while
patients intolerant or resistant to imatinib had 6.3 or 5.4
methylated genes, respectively (P=.0004, chi-square test). A
similar increase in the number of methylated genes in patients
intolerant or resistant to imatinib was also observed in AP, but not
in BP (Table 5). When we analyzed individual genes, the
frequency of aberrant methylation of OSCP1 and NPM2 was
significantly higher in resistant and intolerant patients than in
responsive patients. In the subset of CP patients, aberrant
methylation of OSCP1 was seen only in the patients that were
resistant or intolerant to imatinib (Table S7).
We could not assess the relationship between resistance to
imatinib, DNA methylation and ABL1 mutations, since we had
data on ABL1 mutational status for 10 patients only. Two patients
were responsive to imatinib, negative for ABL1 mutations. They
had 2 and 5 genes hypermethylated, respectively; however, they
did not show hypermethylation of OSCP1 or PDLIM4. One patient
was intolerant to imatinib and negative for ABL1 mutations. The
patient had 6 hypermethylated genes, however, no hypermethyla-
tion of OSCP1 or PDLIM4. Seven patients with known mutational
status of ABL1 were resistant to imatinib. Three of them had
mutations in ABL1, F317L, F359V and a mutation in codon 355,
respectively. These patients had 4, 6 and 6 hypermethylated genes,
respectively. None of these patients showed hypermethylation of
Figure 1. DNA methylation in the K562 leukemia cell line analyzed by MCAM. Red dots correspond to hypermethylated DNA fragments,
green dots show hypomethylated fragments and grey dots depict no significant changes when compared to normal white blood cells. Horizontal
axis, A, average log2 of signal intensity; vertical axis, M, log2 of Cy5/Cy3 normalized fluorescence ratio of K562/normal white blood cells.
doi:10.1371/journal.pone.0022110.g001
Figure 2. DNA methylation and gene expression in the K562
leukemia cell line. Hypermethylation is associated with lower
expression. Bars from left to right, DNA fragments hypomethylated
(green), unchanged (grey), and hypermethylated (red) in K562 located
within 500 bases of gene transcription start sites. The vertical axis shows
differences in z-score normalized log values of gene expression
between the K562 cell line and normal white blood cells. Error bars
show S.E.M.
doi:10.1371/journal.pone.0022110.g002
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negative for ABL1 mutations. They had 5, 7, 8 and 9
hypermethylated genes. Interestingly, three of these 4 patients
had hypermethylated the OSCP1 gene and two had also
hypermethylated the PDLIM4 gene.
DNA methylation and outcome
Having established that DNA methylation is increased in more
advanced stages of CML and in patients resistant or intolerant to
imatinib, we used multivariate analysis to examine if aberrant
methylation is an independent prognostic variable. Since imatinib
treatment changed radically the outcome of CML, we analyzed
separately the groups of patients treated before and in the imatinib
era (Table 6). Hypermethylation of OSCP1 and PDLIM4 genes
were negative risk factors in the pre-imatinib era patients (hazard
ratio 9.6 and 8.1, respectively, P=0.001). Median survival was 1
year for OSCP1-methylated and 0.6 years for PDLIM4-methylated
patients, while the patients with no methylation had median
survival of 4.9 years (Fig. 3). Overall survival of the second group
of 90 patients diagnosed and treated after 2001 (imatinib era) is
shown in Fig. 4 and Fig. 5. Advanced CML stage (hazard ratio 4.0,
P,.001), resistance or intolerance to imatinib (hazard ratio 5.4,
P=.002) and hypermethylation of the PDLIM4 gene (hazard ratio
2.7, P=0.003) were independent prognostic variables (Table 6
and Figure 4). Median survival of the patients with hypermethy-
lated PDLIM4 was 0.9 years while it was 3.9 years in the patients
where PDLIM4 methylation was within the normal range
(Figure 5). When we restricted the analysis to 30 imatinib-
responsive patients only, 3 deaths were observed in 26 patients
with PDLIM4 methylation within normal range, while 1 death was
observed in 4 patients with hypermethylated PDLIM4. However,
the difference in survival was not statistically significant, possibly
due to small number of patients and events. Methylation status of
the LINE-1 repetitive element did not show any association with
the outcome or the stage of the disease.
Discussion
In this study, we have shown that aberrant DNA methylation of
multiple genes characterizes advanced stages of CML and the
disease when resistant to imatinib. Our interpretation is that the
disease progression is associated with epigenetic changes including
aberrant DNA methylation. We speculate that epigenetically
mediated silencing of genes involved in drug transport may also
affect the responsiveness of leukemic cells to imatinib. Given that
CML starts as a genetically homogeneous disease, one can
hypothesize that disease progression and clinical heterogeneity in
CML are related to epigenetic factors including DNA hyper-
methylation. Our data extend previous observations on DNA
methylation in CML and identify multiple new biomarkers in the
disease. Of the genes specifically studied here, some may in fact
contribute to the pathophysiology of disease progression. For
instance, PDLIM4, also known as RIL, is a LIM domain protein
that has tumor-suppressor and pro-apoptotic properties. We have
previously described a significant correlation between methylation
and silencing of this gene [32]. PDLIM4 was found hypermethy-
lated and silenced in prostate cancer. Restoration of its expression
suppressed tumor growth in xenografts [33]. A recent report
suggests that PDLIM4 is important for inactivation of Src and that
epigenetic silencing of PDLIM4 may contribute to aberrant
Table 3. DNA methylation in CML patients.
Gene Cutoff* Patients methylated (%) P value**
(% methylation) CP (n=64) AP (n=41) BP (n=15) Total (n=120)
ABL1 9 52 (81) 37 (90) 14 (93) 103 (86) NS
CDH13 8 47 (73) 34 (83) 14 (93) 95 (79) NS
CDKN2B 7 2 (3) 7 (17) 4 (27) 13 (11) 0.009
DPYS 14 30 (47) 23 (56) 12 (80) 65 (54) NS
NPM2 4 45 (70) 32 (78) 12 (80) 89 (74) NS
OSCP1 4 10 (16) 19 (46) 7 (47) 36 (30) 0.001
PDLIM4 33 8 (13) 12 (29) 5 (33) 25 (21) NS
PGRA 6 36 (56) 33 (80) 10 (67) 79 (66) 0.038
PGRB 11 25 (39) 24 (59) 13 (87) 62 (52) 0.002
TFAP2E 20 32 (50) 32 (78) 11 (73) 75 (63) 0.010
*The highest methylation value observed in normal controls.
**Chi-square test.
doi:10.1371/journal.pone.0022110.t003
Table 4. Methylation and CML stage.
Stage Sum of methylated genes Sum of unmethylated genes P value
Average of methylated genes per
patient
CP 287 353 4.5
AP 253 157 ,0.0001 6.2
BP 102 48 6.8
doi:10.1371/journal.pone.0022110.t004
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our sets of CML patients had a negative prognostic impact
independent of the response to imatinib. We suggest that CML
patients with epigenetically silenced PDLIM4 may particularly
benefit from treatment with Src/Abl inhibitors.
Table 5. Methylation and response to imatinib.
Stage Imatinib response
Sum of methylated
genes
Sum of unmethylated
genes P value
Average of methylated genes
per patient
All stages Responsive 120 180 ,0.0001 4.0
Intolerant 62 38 6.2
Resistant 318 182 6.4
CP Responsive 104 166 0.0004 3.9
Intolerant 38 22 6.3
Resistant 54 46 5.4
AP Responsive 8 12 0.0498 4.0
Intolerant 24 16 6.0
Resistant 186 94 6.6
BP Responsive 8 2 NS 8.0
Intolerant 0 0 N/A
Resistant 78 42 6.5
doi:10.1371/journal.pone.0022110.t005
Figure 3. Methylation of OSCP1 and PDLIM4 in CML patients
from the pre-imatinib era. Hypermethylation of OSCP1 (top) and
PDLIM4 (bottom) is associated with shortened survival. Green line,
methylation within normal range. Red line, hypermethylation.
doi:10.1371/journal.pone.0022110.g003
Figure 4. Advanced stage of CML and resistance or intolerance
to imatinib are associated with shortened survival. Top graph,
green, chronic phase; red, accelerated phase; black, blastic phase.
Bottom graph, green, imatinib-responsive patients; red, patients
resistant or intolerant to imatinib. The figure shows 90 CML patients
(43 CP, 34 AP, 13 BP) from the imatinib era.
doi:10.1371/journal.pone.0022110.g004
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have found to have a potential tumor-suppressor function (and
correlation between methylation and expression) [35]. CDH13,o r
H-cadherin, is a cell adhesion molecule with tumor-suppressor
properties and an established correlation between methylation and
expression [15]. Methylation of CDKN2B or the p15 tumor
suppressor gene is frequently reported in myeloid malignancies
[36]. However, CDKN2B was methylated only in 11% of the CML
patients in our study, and its methylation did not show an
association with shortened survival.
Aberrrant methylation of other genes likely represents passenger
epigenetic defects that reflect the pressures to increase promoter
DNA methylation in neoplastic cells. NPM2, or nucleophosmin 2,
is involved in forming nucleolus-like bodies in oocytes [37]. It is
aberrantly methylated in patients with acute myeloid leukemia [2]
and melanoma [38]. Progesterone receptor methylation has been
reported in leukemia [2] and solid cancers [39,40,41,42]. The role
of DPYS, or dihydropyrimidinase, in the hematopoietic system is
currently unknown, and it may simply be a marker of methylation
defects in CML as is the case in prostate and breast cancer [35].
Methylation of the OSCP1 gene (formerly known as C1orf102 or
NOR1) and its strong association with resistance to imatinib is
intriguing. Aberrant methylation of OSCP1 has been shown in
nasopharyngeal carcinoma [43] and acute myeloid leukemia [2].
This gene codes for an organic solute carrier protein with broad
substrate specificity [44]. The gene product may be involved in the
transport of imatinib to target cells and its silencing may thus
contribute to imatinib resistance.
We found strong concordant methylation for several of the
genes tested, which cannot be explained simply by phase-specific
methylation as concordant methylation also occurred within each
phase. The genes involved do not share features, such as structure,
chromosomal location, or function, and so this concordant
methylation was likely caused by patient-specific pressures to
increase DNA methylation, a phenomenon akin to the CpG island
methylator phenotype described in colon cancer [45]. The causes
of this phenotype remain unknown, and whether the same factors
that lead to it in solid tumors are involved in leukemia
pathogenesis or progression remains to be determined.
Complex changes of DNA methylation in cancer can be
summarized as focal hypermethylation of promoter CpG islands
and global hypomethylation elsewhere, including repetitive
elements [46]. We have previously shown that methylation of
the LINE-1 repetitive element in cancer and leukemia was highly
variable [47]. In this paper, we found that LINE-1 was methylated
above the normal range in 55% of CML patients and only 3% of
patients showed LINE-1 hypomethylation. This is in contrast with
reports of LINE-1 hypomethylation and transcriptional activation
in CML and progressive hypomethylation in the advanced phase
of the disease [48,49].
Further analysis of the data on higher DNA methylation of
OSCP1 and other genes in imatinib-resistant patients is warranted.
It is possible that gene silencing provides an alternative to BCR-
ABL mutations in conferring imatinib resistance. Indeed, only
about 50% of imatinib resistance can be conclusively traced to
acquired mutations [50]. It will therefore be worthwhile to study
mutations and methylation simultaneously and determine whether
there is an inverse correlation between the two events, and
whether it is relevant to resistance to other tyrosine kinase
inhibitors. It is also interesting to consider the fact that DNA
methylation can be partially reversed by treatment with decitabine
or azacitidine. Decitabine has demonstrated single-agent activity
in CML [29], and a combination of decitabine and imatinib has
shown a promising response rate in AP and BP [51]. Given that
many patients with blastic-phase CML continue to die of their
disease, such drug combinations may be relevant even after
therapy with second-generation tyrosine kinase inhibitors.
Supporting Information
Table S1 Bisulfite PCR and pyrosequencing primers.
(XLS)
Table S2 List of genes methylated in the K562 cell line.
Genomic coordinates are based on the March 2006 Assembly
(NCBI36/hg18). XmaFrag_Start, coordinate of the 59 XmaI site.
XmaFrag_End, coordinate of the 39 XmaI site. Gene1, gene with
the start site closest to the 59 XmaI site. Gene2, gene with the start
site closest to the 39 XmaI site. Distance2TSS_Gene1, distance to
transcription start site closest to the 59 XmaI site. Distance2TSS_-
Gene2, distance to transcription start site closest to the 39 XmaI
site. Signal_Intensity_Average, average log2 of signal intensity of
probes covering the XmaI fragment. Log2_Ratio_K562vsControl,
average log2 ratio of Cy5/Cy3 signal intensity of probes covering
the XmaI fragment.
(XLS)
Figure 5. Hypermethylation of the PDLIM4 gene is associated
with shortened survival in CML patients treated in the imatinib
era. Green line, methylation within normal range. Red line, hyper-
methylation. The figure shows 90 CML patients (43 CP, 34 AP, 13 BP)
from the imatinib era.
doi:10.1371/journal.pone.0022110.g005
Table 6. Multivariate analysis of DNA methylation and clinical
data.
Group of patients Independent variable Hazard ratio P value
Pre-imatinib, n=30 OSCP1 methylation 9.6 0.001
PDLIM4 methylation 8.1 0.001
Imatinib era, n=90 Disease stage 4.0 ,0.001
Imatinib resistance/intolerance 5.4 0.002
PDLIM4 methylation 2.7 0.003
doi:10.1371/journal.pone.0022110.t006
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22110Table S3 Genes methylated in the K562 leukemia cell
line are enriched for targets of Polycomb in ES cells.
(XLS)
Table S4 Gene categories affected by DNA methylation
in K562.
(XLS)
Table S5 LINE-1 methylation.
(XLS)
Table S6 Spearman correlation between methylation of
different genes. In each cell, the top number is the correlation
coefficient r. The bottom number is a P value. To correct for
multiple comparisons, P,.001 was considered significant.
(XLS)
Table S7 Methylation of individual genes and the
response to imatinib.
(XLS)
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